Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors

Nelleke Tolboom; Antoine Verger; Matthias Preusser; Marjolein Geurts; Philip Scheltens; Nathalie Lisa Albert

doi:10.1093/noajnl/vdag043

Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors

Nelleke Tolboom^*
, Antoine Verger
, Matthias Preusser
, Marjolein Geurts
, Philip Scheltens
, Nathalie Lisa Albert

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

The evolution of amyloid PET in Alzheimer’s disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET’s trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.

Original language	English
Article number	vdag043
Number of pages	4
Journal	Neuro-oncology advances
Volume	8
Issue number	1
DOIs	https://doi.org/10.1093/noajnl/vdag043
Publication status	Published - 1 Jan 2026

Access to Document

10.1093/noajnl/vdag043Licence: CC BY

Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors Final published version, 326 KBLicence: CC BY

Cite this

@article{e5c40dcfefb64c6e9400b7178314cfbc,

title = "Drawing parallels between amyloid PET in Alzheimer{\textquoteright}s disease and amino acid PET in primary and secondary brain tumors",

abstract = "The evolution of amyloid PET in Alzheimer{\textquoteright}s disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET{\textquoteright}s trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.",

author = "Nelleke Tolboom and Antoine Verger and Matthias Preusser and Marjolein Geurts and Philip Scheltens and Albert, \{Nathalie Lisa\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2026. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",

year = "2026",

month = jan,

day = "1",

doi = "10.1093/noajnl/vdag043",

language = "English",

volume = "8",

journal = "Neuro-oncology advances",

issn = "2632-2498",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors

AU - Tolboom, Nelleke

AU - Verger, Antoine

AU - Preusser, Matthias

AU - Geurts, Marjolein

AU - Scheltens, Philip

AU - Albert, Nathalie Lisa

PY - 2026/1/1

Y1 - 2026/1/1

N2 - The evolution of amyloid PET in Alzheimer’s disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET’s trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.

AB - The evolution of amyloid PET in Alzheimer’s disease illustrates the potential path of amino acid PET in neuro-oncology. Initially seen as of limited value, amyloid PET ultimately enhanced diagnostic accuracy, guided management, and became central once therapies demonstrated PET-measured efficacy. Amino acid PET for CNS tumors is at a similar turning point. It refines diagnosis, distinguishes progression from treatment effects, and supports treatment planning. As demand grows and tracer access improves, amino acid PET could follow amyloid PET’s trajectory: emerging as a key tool in precision medicine and clinical management and as a surrogate endpoint in therapeutic trials.

UR - https://www.scopus.com/pages/publications/105033283561

U2 - 10.1093/noajnl/vdag043

DO - 10.1093/noajnl/vdag043

M3 - Article

AN - SCOPUS:105033283561

SN - 2632-2498

VL - 8

JO - Neuro-oncology advances

JF - Neuro-oncology advances

IS - 1

M1 - vdag043

ER -

Drawing parallels between amyloid PET in Alzheimer’s disease and amino acid PET in primary and secondary brain tumors

Abstract

Access to Document

Other files and links

Fingerprint

Cite this